>
Switch to:

Allergy Therapeutics Price-to-Owner-Earnings

: 49.80 (As of Today)
View and export this data going back to 2004. Start your Free Trial

As of today (2021-10-27), Allergy Therapeutics's share price is $0.498. Allergy Therapeutics's Owner Earnings per Share (TTM) ended in Jun. 2021 was $0.01. It's Price-to-Owner-Earnings for today is 49.80.


The historical rank and industry rank for Allergy Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

OTCPK:AGYTF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 8.04   Med: 59   Max: 332.5
Current: 33.5

8.04
332.5

During the past 13 years, the highest Price-to-Owner-Earnings of Allergy Therapeutics was 332.50. The lowest was 8.04. And the median was 59.00.


OTCPK:AGYTF's Price-to-Owner-Earnings is ranked lower than
68% of the 44 Companies
in the Drug Manufacturers industry.

( Industry Median: 17.71 vs. OTCPK:AGYTF: 33.50 )

As of today (2021-10-27), Allergy Therapeutics's share price is $0.498. Allergy Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.00. Therefore, Allergy Therapeutics's PE Ratio for today is 249.00.

As of today (2021-10-27), Allergy Therapeutics's share price is $0.498. Allergy Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was $0.00. Therefore, Allergy Therapeutics's PE Ratio without NRI for today is 249.00.

During the past 13 years, Allergy Therapeutics's highest PE Ratio without NRI was 307.50. The lowest was 10.23. And the median was 60.63.


Allergy Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for Allergy Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Price-to-Owner-Earnings
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 7.50 23.00

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Price-to-Owner-Earnings Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 7.50 - 23.00

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Price-to-Owner-Earnings Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Price-to-Owner-Earnings falls into.



Allergy Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Allergy Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.498/0.01
=49.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Allergy Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)